CLODERM (clocortolone pivalate) by Enterprise Therapeutics is clinical pharmacology topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1977.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
CLODERM (clocortolone pivalate) is a topical corticosteroid cream that reduces inflammation, itching, and skin vascularity through anti-inflammatory and antipruritic mechanisms. It is applied directly to affected skin areas for inflammatory dermatologic conditions. The drug works by inhibiting inflammatory mediators, though the exact mechanism remains incompletely understood.
Approaching loss of exclusivity with minimal Part D utilization signals a contracted commercial footprint and likely smaller brand team focused on managed care and retention.
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CLODERM at Enterprise Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CLODERM offers minimal career momentum; the product is a legacy brand in a commoditized market with shrinking utilization and no innovation pipeline. Roles available are typically defensive (retention, pricing) rather than growth-oriented, making this a consolidation or transition assignment rather than a high-visibility opportunity.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo